New York-based Bristol-Myers Squibb (NYSE: BMY) has received approval from the US Food and Drug Administration for Opdivo (nivolumab) in a new indication.
The immunotherapy may now be marketed as a treatment for adult and pediatric patients with certain kinds of colorectal cancer that have progressed despite treatment.
The approval was given under the agency’s accelerated approval based on clinical data from the CheckMate trial, related to overall response rate and duration of response. Continued approval may depend on confirmatory trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze